Vasquez-Rios, George
Moledina, Dennis G.
Jia, Yaqi
McArthur, Eric
Mansour, Sherry G.
Thiessen-Philbrook, Heather
Shlipak, Michael G.
Koyner, Jay L.
Garg, Amit X.
Parikh, Chirag R.
Coca, Steven G.
,
Article History
Received: 20 March 2022
Accepted: 8 December 2022
First Online: 25 December 2022
Declarations
:
: All participants provided informed consent prior to the participation in this study. The Ethics review board committee of Yale University School of Medicine, Duke University, and London Health Sciences Centre approved the current research study. All participants provided written informed consent. The reporting of this study follows guidelines set out in the Strengthening the Reporting of Observational Studies in Epidemiology statement. All methods were performed in accordance with the Declaration of Helsinki.
: All authors provided consent for publication of the current study.
: The research reported in this article was supported by the American Heart Association Clinical Development Award, as well as by the grant R01HL-085757 from the National Heart, Lung, and Blood Institute. C.R.P. is also supported by an NIH grant (K24DK090203). S.G.C., A.X.G., and C.R.P. are also members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Consortium (U01DK082185). S.G.C. M.G.S, and C.R.P. are members and are supported in part by the Chronic Kidney Disease Biomarker Consortium (1U01DK106962-01). DGM is supported by K23DK117065. JLK is supported by R21DK113420. The study was also supported by CTSA Grant Number UL1 RR024139 from the National Center for Research Resources (NCRR). This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC); Dr. Amit Garg is supported by the Dr. Adam Linton Chair in Kidney Health Analytics; no other relationships or activities that could appear to have influenced the submitted work. S.G.C. and C.R.P. are on the Advisory Board of RenalytixAI, and both own equity in the same. S.G.C. has served as a consultant for AKI therapeutics for Quark Biopharma and CHF Solutions. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions, and statements expressed herein are those of the authors, and not necessarily those of CIHI. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. All the other authors declared no competing interests.